Policy
FDA Adds Optic Neuropathy Warning to GLP-1 RA Drug Labels
Science-Based Medicine · By David Weinberg ·
The Brief
- The FDA has added an optic neuropathy warning to the labels of GLP-1 receptor agonist (GLP-1 RA) drugs.
- Science-Based Medicine says a causal relationship between GLP-1 RAs and "eye stroke" remains tenuous.
- The same source describes the FDA's decision as reasonable.
Why it matters
The label change reflects a regulatory decision made despite a causal link that is still described as tenuous, so readers should weigh the warning against the limited evidence behind it.
Who’s affected
- patients taking GLP-1 receptor agonist drugs
- clinicians prescribing GLP-1 receptor agonist drugs
- #glp-1
- #drug safety
- #optic neuropathy
- #fda
- #medication labels
A causal relationship between GLP-1 RAs and "eye stroke" remains tenuous, but the FDA’s decision seems reasonable The post FDA Adds Optic Neuropathy Warning to GLP-1 RA Drug Labels first appeared on Science-Based Medicine .